Sign in

CIK 0001348362

  • Non-accelerated filer
  • Smaller reporting company

Lexaria Bioscience Corp.

Sign in to watch
Ticker
LEXX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Aug 31
Incorporated
NV
Entity type
Operating
EIN
202000871
Phone
+1 250-765-6424
Business address
100 - 740 MCCURDY ROAD, KELOWNA, British Columbia, Canada, V1X 2P7
Former names
Lexaria Corp., LEXARIA CORP.
  1. 4 Open-market buy CEO bought 7,000 shares at an average $0.13 ($900)
  2. 4 Open-market buy CEO bought 32,500 shares at an average $0.13 ($4,368)
  3. 4 Open-market buy CEO bought 8,990 shares at $0.15 ($1,357)
  4. 4 Open-market buy CEO bought 20,000 shares at an average $0.17 ($3,325)
  5. 4 Open-market buy CEO bought 3,500 shares at $0.20 ($700)
  6. 4 Open-market buy CEO bought 26,000 shares at an average $0.22 ($5,697)
  7. 4 Grant or award Director acquired 10,000 shares (grant or award)
  8. 4 Grant or award President acquired 55,000 shares (grant or award)
  9. 4 Open-market buy CEO bought 5,000 shares at an average $0.22 ($1,075)
  10. 4 Grant or award CEO acquired 1,073,834 shares (grant or award)
  11. 4 Grant or award Director acquired 20,000 shares (grant or award)
  12. 4 Grant or award CFO acquired 14,125 shares (grant or award)
  13. 4 Open-market buy CEO bought 5,000 shares at $0.20 ($975)
  14. 4 Open-market buy CEO bought 4,000 shares at an average $0.20 ($799)
  15. 4 Open-market buy CEO bought 20,000 shares at an average $0.19 ($3,820)
  16. 4 Open-market buy CEO bought 20,000 shares at an average $0.19 ($3,855)
  17. 4 Open-market buy CEO bought 3,500 shares at an average $0.21 ($725)
  18. 4 Open-market buy CEO bought 29,500 shares at an average $0.21 ($6,286)
  19. 4 Open-market buy CEO bought 4,000 shares at an average $0.23 ($934)
  20. 4 Open-market buy Director bought 100,000 shares at $0.19 ($19,000)

Page 9 of 21 · 420 filings